Concepedia

James Capobianchi

JC

Statistics

Publications

5

Citations

403

H-Index

5

Active since

2013

Affiliations

University of Pennsylvania(Current)

Children's Hospital of Philadelphia

Novartis (United States)

James Capobianchi is an author at University of Pennsylvania specializing in t cell immunity, cancer research, and cancer therapeutics.

Top concepts

Publications per year

2013–2016

5

Publications

5

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim et al. · Blood · 2016 · 258 citations · Full text

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

David Porter, J. Joseph Melenhorst, Wei‐Ting Hwang et al. · Blood · 2014 · 64 citations

Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

David L. Porter, Jan J. Melenhorst, Wei‐Ting Hwang et al. · Journal of Clinical Oncology · 2016 · 32 citations

, , +22

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

David L. Porter, Michael Kalos, Stephan A. Grupp et al. · Blood · 2013 · 29 citations

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, Michael Kalos, Stephan A. Grupp et al. · Blood · 2013 · 20 citations

1–5 of 5